Want to join the conversation?
The Kenilworth, New Jersey-based pharma company $MRK said that despite strong currency headwind, the company was able to deliver growth in 2015 and expects to deliver growth in 2016 as well. 2016 is the year representing the first year in which $MRK's new product sales growth driven by ZEPATIER and KEYTRUDA are expected to contribute meaningfully.
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.